Atrys Health loses 23.5 million euros in 2022, with turnover up 54.5%

Atrys Health loses 23.5 million euros in 2022, with turnover up 54.5%

In 2023, the company will focus on consolidating the various business lines and continuing to innovate

Atrys Health announced Wednesday an accounting loss of €23.5 million in 2022 due mainly to expenses associated with the company’s strong inorganic growth, amortizations of acquisitions carried out and the optimization of the group structure executed in 2022. Without these effects, the net accounting result would have been positive, it explained in a statement sent to the Spanish National Securities Market Commission (CNMV).

In its first year as a member of the Continuous Market of the Spanish Stock Exchange, Atrys’ turnover improved by 54.5% compared to the previous year, reaching 186.9 million euros.

Gross margin for 2022 was 149.7 million euros, 52.6% higher than in the previous year, while at pro forma level it reached 158.8 million euros.

Adjusted EBITDA grew to EUR 41.3 million, up 60.5% from EUR 25.7 million in the previous year. On a pro forma basis, revenues amounted to 210.9 million euros and adjusted EBITDA reached 47.2 million euros.

The company emphasized that, in the current environment of inflationary tension, it has maintained its gross and adjusted EBITDA margins.

CAPEX investment increased by 63.4% to EUR 14 million in 2022. 5 million of the total investment corresponded to growth CAPEX, associated with the opening of the nuclear medicine center at SDJ Pediatric Cancer Center and the pathology laboratory in Madrid, as well as two oncology treatment centers in Mexico.

Looking ahead to 2023, Atrys has announced that it will focus on consolidating the different lines of business and continuing to innovate technologically to offer the most advanced diagnostics and treatments. Thus, the company has set a double-digit growth target, specifically between 10 and 13%, both in terms of turnover and adjusted EBITDA.

Santiago de Torres, CEO of Atrys, said that “2022 has been a challenging year, with a complex macroeconomic context, in which we have once again demonstrated our solvency and capacity for growth, maintaining the confidence of investors and winning the backing of new shareholders. This year we will focus on strengthening the different business areas of Atrys, always with an eye on continuing to offer patients the best healthcare service and on creating value for our shareholders”.

Samuel Edwards
Samuel Edwards is the name you must have heard many times while reading reports related to Finance, that's what he is good at. From Major Investments to Stock Market Updates, he got 'em all. Be ready to blow your mind by the mind-blowing reports of Finance World from Samuel Edwards.